tag:blogger.com,1999:blog-2741672436160438708.post8452783227442147581..comments2024-03-06T05:15:14.324-08:00Comments on Learning from and about cancer (chronic lymphocytic leukemia or CLL) by Dr. Brian Koffman: ASH 2013: Dr. John Pagel Discusses Radio-Immune Therapy (RIT) in Chronic Lymphocytic Leukemia (CLL)Brian Koffmanhttp://www.blogger.com/profile/13250684684103918493noreply@blogger.comBlogger3125tag:blogger.com,1999:blog-2741672436160438708.post-18382350842047873832014-05-18T10:19:19.477-07:002014-05-18T10:19:19.477-07:00I've never heard of RIT thanks for bringing th...I've never heard of RIT thanks for bringing this to our attention Brian. It sounds promising although with radioactivity going through the blood and tissues, it seems off target harm would be a significant issue, at least to this untrained eye. I hope of course my gut is way off.<br /><br />This is another frustrating example of the "CLL industry" atmosphere slowing a full steam ahead push on the most promising therapies, particularly in combo which is what CLL patients need most. A lot of unnecessary process friction and entrenched interests are adding years to our waits to see this stuff in clinic, and ultimately we know what that means in terms of lost patients.Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-2741672436160438708.post-66811659205105617572014-05-18T10:18:07.311-07:002014-05-18T10:18:07.311-07:00On a more uplifting note..I religiously read your ...On a more uplifting note..I religiously read your blog and I cant tell you what it means to me and so many other, you're incredibly brave an inspiring..thank you so much for what u do, means more than you'll ever kno..god bless an keep up the good fightCJhttps://www.blogger.com/profile/12408465189971576272noreply@blogger.comtag:blogger.com,1999:blog-2741672436160438708.post-30679974392615005002014-05-18T05:25:31.175-07:002014-05-18T05:25:31.175-07:00Interesting But....
I have a problem with any &quo...Interesting But....<br />I have a problem with any "new" therapy approach that targets healthy as well as cancerous cells. A ROR1 targeted drug delivery might turn my rotors more. <br /><br />I would have been interested to hear John's take on the CD20 shaving or internalization phenomena that had been described by the work of Dr. Taylor. The documentation of stealth cells having no CD20 target after Rituximab Therapy to hone in on would seem to thwart the strategy. I suppose that the newer generation of CD20 mAbs that target the closer epitope of CD20 might avoid this issue but the use of CD20 mAbs as a first therapy should be discussed more.<br /><br />great job pursuing the leads,<br /><br />WWWAnonymoushttps://www.blogger.com/profile/08783029423801860411noreply@blogger.com